GlassScriptPhysician profile
Bryan C Mullins
NPI 1659589166
$3,425.95
in general payments reported to CMS, 2019-2025
31 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $599 · 2020: $271 · 2021: $376 · 2022: $393 · 2023: $295 · 2024: $1,172 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $905 · Food and Beverage: $884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $904.58 |
| Food and Beverage | $883.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $904.58 | 2024 | |
| Abbvie INC. | $849.47 | 2019-2024 | |
| Astellas Pharma US INC | $384.41 | 2019-2025 | Veozah |
| Hologic Sales and Service, LLC | $158.41 | 2019-2025 | Novasure |
| Exeltis, USA INC. | $135.69 | 2022-2025 | Slynd |
| Mayne Pharma Commercial LLC | $122.38 | 2021-2023 | |
| Therapeuticsmd, INC. | $101.83 | 2019-2022 | |
| Pfizer INC. | $84.10 | 2019-2025 | |
| Amgen INC. | $77.79 | 2019-2023 | Evenity, Prolia |
| Sage Therapeutics, LLC | $74.80 | 2024-2025 | Zurzuvae |
| Millicent US INC | $65.63 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Organon LLC | $57.16 | 2022-2025 | Nexplanon |
| Shield Therapeutics INC | $56.33 | 2023-2025 | Accrufer |
| Dexcom, INC. | $36.64 | 2023 | Dexcom G6 Transmitter |
| Duchesnay USA Incorporated | $30.83 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $30.33 | 2019-2021 | |
| Myovant Sciences INC. | $25.45 | 2022 | |
| Baxter Healthcare | $24.81 | 2022 | |
| Solventum Corporation | $24.12 | 2025 | Prevena |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.26 | 2023 | Xifaxan, Trulance |
| Coopersurgical, INC. | $19.41 | 2020 | |
| Scynexis, INC. | $18.30 | 2022 | |
| Urovant Sciences INC | $17.32 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.19 | 2022 | |
| Lilly USA, LLC | $15.09 | 2024 | Zepbound |
| Agile Therapeutics, INC. | $13.44 | 2021 | |
| Sumitomo Pharma America, INC. | $13.41 | 2023 | Myfembree |
| Allergan, INC. | $13.38 | 2020 | |
| Eisai INC. | $12.30 | 2021 | |
| Radius Health, INC. | $11.80 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Mullins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.